Biological Dynamics CEO Raj Krishnan and CFO Kevin Han shared what informs their vision for developing liquid biopsies to detect cancer at the earliest stages to ensure the best outcome for patients.
The molecular diagnostic company has brought in a new round of funding primarily dedicated toward securing regulatory clearance for the company's oncology diagnostic program TR(ACE) assay.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
It takes several months and several tests to determine whether chemotherapy is working. San Diego startup Biological Dynamics just raised $22.8 million for its simple, inexpensive blood test that can tell whether a patient is responding to a cancer treatment.